ORIC Pharmaceuticals (ORIC) shareholders back updated equity plan and annual say-on-pay
Rhea-AI Filing Summary
ORIC Pharmaceuticals, Inc. reported results of its annual stockholder meeting and an update to its 2020 Equity Incentive Plan. Stockholders approved an amended and restated plan that changes how many shares can be added each year and clarifies limits on incentive stock options.
The plan’s annual “evergreen” increase was reduced from 5% to 4% of outstanding common shares while removing a prior 2,656,500-share annual cap, and it now caps shares issuable via incentive stock options at 10,000,000, subject to the overall share reserve. The amended plan also eliminates the administrator’s ability to run exchange or repricing programs for outstanding awards or allow transfers of awards to third parties.
At the meeting, held on June 18, 2026, stockholders elected two Class III directors, ratified KPMG LLP as auditor for the year ending December 31, 2026, approved executive compensation on an advisory basis, and chose to hold future advisory votes on executive pay every year. Of 103,517,562 shares outstanding as of April 20, 2026, 94,571,281 were represented, reflecting 91.36% participation.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
evergreen provision financial
incentive stock options financial
broker non-votes financial
advisory (non-binding) basis financial
equity incentive plan financial
FAQ
What change did ORIC (ORIC) make to its 2020 Equity Incentive Plan?
How does the new evergreen provision work in ORIC’s equity plan?
What is the new limit on incentive stock options under ORIC’s plan?
What other items did ORIC stockholders approve at the 2026 annual meeting?
AI-generated analysis. How Rhea-AI works. Not financial advice.